A transdermal patch contains a water-based solution containing electrolytes, vitamins, and at least one permeation enhancer. The water-based solution also acts as an adhesive matrix which binds the patch together. The solution is transferred to the body via an embossed release liner. In use, the permeation of electrolytes into the bloodstream improves the body's ability to manage hydration. The permeation enhancer increases the porosity of the skin in contact with the transdermal patch to make possible the permeation of the solution into the body. Critical proportions of solvent, solutes, and permeation enhancers are disclosed which have been found to make permeation of otherwise non-absorbable ingredients possible.

A comfort article may comprise a proximal layer that adheres to the skin of a foot, and a non-slip distal layer with a high coefficient of friction that prevents footwear from sliding with respect to the foot without adhering to or sticking to the shoe. The proximal layer comprises a sticky adhesive surface or dry adhesive. The comfort article is cutout into various shapes and applied to one or more locations on a user's foot at a point of contact within the shoe that is intended to prevent the foot from moving with respect to the shoe. The comfort articles may also be supplied as a kit with various precut devices configured to fit certain types of footwear and accommodate user preferences. A cushion layer(s) may be interposed between the proximal layer and distal layer.

A method of administering a pharmaceutical agent to the circulatory system through the skin of a mammal may include the steps of loading a pharmaceutical agent in a transdermal patch, applying the transdermal patch to the skin of the mammal and releasing the pharmaceutical agent into the circulatory system at a rate of at least 0.001 micrograms per hour up to 50.0 micrograms per hour per kilogram of bodyweight of the mammal. The drug delivery system may comprise a transdermal patch loaded with the pharmaceutical agent. The patch may include a porous membrane and an outer impermeable cover defining a cavity therebetween. A plurality of drug delivery layers may be disposed between the porous membrane and the impermeable cover. A lipophilic/hydrophilic suspension may be disposed between the drug delivery layers.

A composition for relieving pain, and methods of making and using the composition, whereby the composition comprises an amount of sugar or sugar alcohol; and an amount of vehicle; wherein the composition is formulated for transdermal administration; and wherein, upon transdermal administration, the composition is effective to relieve pain. As to particular embodiments, the composition further comprises an amount of alkalizing agent.

A therapeutic kinesiology tape has an elastic fabric with a back side and a face side, the elastic fabric containing both lateral and longitudinal fibers which intersect to form a woven layer. The therapeutic kinesiology tape further has an adhesive material formulated with a transdermal cannabinoid formula and disposed on the back side of the elastic fabric, wherein a dose of the cannabinoid is transferred to the user after transdermal administration.

The present invention provides a pharmaceutical composition containing the following compound having antiviral action:

##STR00001##

wherein each of the symbols is defined in the specification.

Flexible packages, transdermal drug delivery devices, and methods for fabricating packages are provided. An exemplary flexible package includes a chemical and moisture resistant layer formed from poly(chlorotrifluoroethylene-co-vinylidene fluoride) (P(CTFE-co-VDF)) copolymer. Further, the exemplary flexible package includes a substance to be delivered. The substance is applied to or enclosed by the chemical and moisture resistant layer.

Melts or ionic liquids containing amorphous propranolol, topical formulations and patches for transdermal drug delivery, and methods of making and using thereof are described herein. The melts or ionic liquids may be in a topical drug delivery formulation or patch to be applied to the skin. The drug delivery formulation or patch contains a sufficient amount of the amorphous propranolol to deliver a therapeutically effective amount of the amorphous propranolol to the patient in need of treatment, such as for the treatment or amelioration of infantile hemangioma. The formulations have a low viscosity and reduced skin irritation compared to the crystalline propranolol free base (PFB). The melts or ionic liquids can be formed by a salt metathesis reaction.

Provided are methods for continuously administering to a subject in need of treatment a formulation comprising an immunomodulatory imide compound. In some embodiments, the method are for use in treating multiple myeloma, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes, mantle cell lymphoma, hematologic cancers, or solid tumor cancers.

Provided herein are transdermal delivery devices comprising dextromethorphan. The transdermal delivery device can be characterized by the novel design, for example, with an adhesive layer and a reservoir layer, with an adhesive layer comprising a mixture of two adhesives, and/or with a skin permeation enhancer, e.g., in an amount that can significantly enhance the flux of dextromethorphan. The transdermal delivery device can also be characterized by its in vitro and/or in vivo release profile, for example, that can provide a desired pharmacokinetic profile described herein. Also provided herein are methods of administering dextromethorphan, and methods of treating a disease or disorder described herein, using the transdermal delivery device herein.